FDA approves Lilly's lung cancer drug

Nov 24 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Eli Lilly & Co's cancer treatment, Portrazza, in combination with two forms of chemotherapy to treat patients with advanced squamous non-small cell lung cancer.